For instance, TKIs can reduce the secretion of immunosuppressive cytokines such as TGF-β and IL-10 and inhibit immunosuppressive regulatory T cells, macrophages and myeloid-derived suppressor cells.[12] TKIs promote tumor vascular normalization and consequently improve the delivery of embolism agents and systemic anticancer drugs to optimize the anticancer effects of TACE and immunotherapy.[13] Many other studies are currently underway to validate the efficacy and safety of various combination therapies. Here, TGFB1 is linked to neoplasm.